MedPath

Endomina Diverticulum

Not Applicable
Terminated
Conditions
Oesophageal Disease
Interventions
Device: Endomina
Registration Number
NCT03609073
Lead Sponsor
Erasme University Hospital
Brief Summary

Esophageal diverticulum is a rare disease. Majority comes form the pharyngo-esophageal junction (70 % Zenker's Diverticulum), 10% are mediothoracic and 20% epiphrenic. Zenker's diverticulum is well treated with endoscopy (efficacy around 80%, complications around 5%) (1). For medio or epihrenic diverticulum, the classic treatment is surgery (diverticulectomy with or without anti-reflux surgery) but is associated with 33% morbidity and 9% mortality (2). Recently another technique involving magnet was described (3). Five patients were treated with success.

Considering the surgical risk, other techniques need to be evaluated. Using the Endomina device, sutures can be apposed between the foot of the diverticulum and the esophageal lumen. If necessary the bridge between the diverticulum and the esophagus can be cut with needle knife as described in Zenker's diverticulum treatment.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
4
Inclusion Criteria
  1. Symptomatic medio or epiphrenic diverticulum.
  2. Age between 18-80 years;
  3. Must be able to comply with all study requirements for the duration of the study as outlined in the protocol. This includes complying with the visit schedule as well as study specific procedures such as: clinical assessment, endoscopy, radiography, as well as laboratory investigations;
  4. Must be able to understand and be willing to provide written informed consent;
  5. Must live within 75 km of the treatment site;
Exclusion Criteria
  1. Achalasia and any other esophageal motility disorders.
  2. Severe esophagitis
  3. Gastro-duodenal ulcer
  4. Severe renal, hepatic, pulmonary disease or cancer;
  5. GI stenosis or obstruction;
  6. Pregnancy, breastfeeding or willing to become pregnant in the coming 18 months;
  7. Anticoagulant therapy;
  8. Currently participating in other study

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
InterventionEndomina-
Primary Outcome Measures
NameTimeMethod
Incidence of all Adverse Device Effectsone year from procedure

Safety will be characterized by the incidence of all Adverse Device Effects

Secondary Outcome Measures
NameTimeMethod
Dysphagiaone year from procedure

Efficacy will be measured by the Dakkak and Bennett score of Dysphagia (Score 0 - no dysphagia to 4 - aphagia)

Trial Locations

Locations (1)

Gastroenterology Department Erasme Hospital

🇧🇪

Brussels, Belgium

© Copyright 2025. All Rights Reserved by MedPath